A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants

Ki vehet részt

• Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)
• Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study
• Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication
• The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
• Must have received the information note, given his/her oral agreement and has not objected to the collection of his/her data in accordance with French requirements

Ki nem vehet részt

• Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment
• Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase [JAK] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA/PsO at the same time
• Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent)
• Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis)
• Unwilling or unable to participate in long-term data collection
• Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study
• Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization